Share the Video:

Psychedelics, Exceptionalism, and Other Drugs

Ethan Nadelmann

I am very much a psychedelic (and cannabis) exceptionalist when it comes to my own drug use – and also when assessing the relative benefits and risks of varied psychoactive drugs. But that must not extend to a sense of exceptionalism when it comes to either the core principles or the broader agenda of drug policy reform consciousness and activism. Psychedelics offer great promise in alleviating pain, addiction and other maladies. Psychedelic policy reform provides inspiration and models for enlisting military veterans and building bipartisan coalitions. These advances will mean all the more to the extent they extend to and embrace the broader world of drugs and drug policy reform.

Become a MAPS Member with a monthly donation

As a Member, you’re not just making a donation — you’re joining a community that is at the forefront of advancing research, changing policy, and evolving education around psychedelics. Join us in shaping a future where these life-changing tools are available to those who need them most.

Psychedelics: Spirituality, Mindfulness, and Mortality – Personal reflections and visions for the future

Roland Griffiths, Ph.D., from Johns Hopkins University, leads research on psilocybin's effects, including therapeutic studies for psychological distress, depression, addiction, and brain imaging for neural mechanisms.

Roland Griffiths

PS2023 Policy and Advocacy Psychedelic Assisted Therapy Psychedelic Science Research Social and Cultural Spirituality

Tempering Psychedelics: A Conversation with Michael Pollan and Bob Jesse

Michael Pollan, an influential author, sparked interest in psychedelic research with his book "How to Change Your Mind." Bob Jesse, a key figure in the resurgence of psychedelics, has made

Robert Jesse, Michael Pollan

PS2023 MDMA Policy and Advocacy Psychedelic Assisted Therapy Psychedelic Science Research Research and Science

Priorities for the next generation of psychedelic science

NIMH Director Joshua A. Gordon and trauma researcher Barbara O. Rothbaum discuss the current state and future directions of psychedelic research, emphasizing the need for deeper understanding and robust study

Joshua A Gordon

PS2023 Policy and Advocacy Psychedelic Assisted Therapy Psychedelic Science Research Research and Science Resources for Therapists

The State of Psychedelic Research Since 2017

Drs. Summergrad and Insel reflect on the progress and remaining questions in psychedelic science since 2017. They delve into topics like efficacy, regulation, therapy, and provider experience.

Paul Summergrad, Tom Insel, Rachel Nuwer

PS2023 Policy and Advocacy Psychedelic Assisted Therapy Psychedelic Science Psychedelic-AT Research and Science Social and Cultural

A Family Legacy: From a Mother to her Sons

Rick Doblin discusses growing up with the "queen of psychedelics", Rock and Cosmo's paths to this work, challenges of working with family, and their shared vision for the psychedelic renaissance.

Amanda Feilding, Rock Feilding-Mellen, Cosmo Fielding Mellen

PS2023 Harm Reduction Integration Policy and Advocacy Psychedelic Assisted Therapy Psychedelic Science Research

Responding to Crises and Calls with Psychedelic Harm Reduction

Panelists from Zendo Project, Fireside Project, Kosmicare, and Anashim Tovim discuss harm reduction strategies in the psychedelic ecosystem, emphasizing innovation, compassion, and scientific expertise in diverse settings. They provide case

Joshua White, Daniel E Martin, Pinni Baumol, Shirelle Noble, Ben Halper

PS2023 Business Policy and Advocacy Psychedelic Assisted Therapy Psychedelic Science Public Benefit Research and Science

The evolving financial landscape for psychedelic medicine

Funding for psychedelic medicine is evolving, with a rise in commercial capital alongside philanthropic support. Balancing financial interests with equitable access and learning from scaling challenges are key considerations.

Henry Elkus

PS2023 Policy and Advocacy Psychedelic Assisted Therapy Psychedelic Science Public Benefit Research Social Justice

TREAT CALIFORNIA-Providing $5 Billion to Fund Psychedelic Research and Therapies

TREAT California initiative aims to transform mental healthcare in California with $5 Billion funding for psychedelic medicine research and access, inspired by successful stem cell agency model.

Jeannie Moller Fontana

PS2023 Harm Reduction Health Conditions Policy and Advocacy Psychedelic Science Research Substance Use Disorder

The Canadian Psychedelic Survey; Results of a Large Cross-Sectional Survey of Canadian Adults Who Use Psychedelics

Canadian Psychedelic Survey collected real-world evidence from 2393 Canadian adults on psychedelic use, revealing patterns, effects, and reasons for use. Results may influence policy and treatment approaches.

Philippe Lucas

Psychedelics, Exceptionalism, and Other Drugs

Become a MAPS Member with a monthly donation

Related Videos